ReviewFrontiers in endocrinology2026
Disrupted thyroid hormone-mitochondrial coupling in diabetic cardiomyopathy: a candidate upstream amplifier of metabolic and redox maladaptation.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy (DCM) is characterized by mitochondrial metabolic inflexibility, redox imbalance and defective organelle quality control, yet the endocrine program coordinating these abnormalities remains incompletely defined. Thyroid hormone (TH) is a major regulator of cardiac energy metabolism and mitochondrial adaptation. In experimental diabetes, myocardial triiodothyronine (T3) can decline despite preserved circulating thyroid hormone concentrations, accompanied by type 3 iodothyronine deiodinase (DIO3) induction and altered TH transport. We propose that this local defect disrupts thyroid hormone-mitochondrial coupling and may thereby constrain adaptation of substrate oxidation, oxidative phosphorylation, redox defense and organelle turnover. Preclinical diabetic-heart studies demonstrate local TH dysregulation and show that appropriately dosed T3 treatment can reverse selected structural and functional abnormalities. Complementary cardiac studies identify mitochondrial biogenesis, reactive oxygen species control, mitophagy and calcium handling as plausible downstream effectors. Together, these findings support impaired local TH signaling as an underrecognized candidate upstream mechanism linking the diabetic endocrine environment to mitochondrial maladaptation. A tissue-specific therapeutic-window model may reconcile the adverse consequences of both deficient and excessive TH signaling while providing a framework for biomarker development, mechanistic testing and precision intervention in DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.